StoxCohance Lifesciences vs NATCO Pharma: share price & financials comparison
NSE: COHANCE vs NATCOPHARM · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Cohance Lifesciences vs NATCO Pharma at a glance
Cohance Lifesciences (COHANCE) has a market capitalisation of ₹16,588 Cr, against ₹14,445 Cr for NATCO Pharma (NATCOPHARM). Over the past year NATCO Pharma has returned -2.5%, compared with -44.9% for Cohance Lifesciences. On valuation, NATCO Pharma trades at a lower P/E of 12.6 versus 156.1. NATCO Pharma earns a higher return on equity (12.4% vs 2.7%). Cohance Lifesciences comes out ahead on growth, financial health and technicals. NATCO Pharma comes out ahead on size, valuation, profitability and momentum. Across the scored metrics below, Cohance Lifesciences leads on 4 and NATCO Pharma on 12. On StoxGud's 10-point checklist, Cohance Lifesciences scores 3/10 and NATCO Pharma scores 4/10.
| Metric | Cohance Lifesciences | NATCO Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹16,588 Cr | ₹14,445 Cr |
| Revenue (latest FY) | ₹2,269 Cr | ₹4,078 Cr |
| Net profit (latest FY) | ₹179 Cr | ₹1,418 Cr |
| Valuation | ||
| P/E | 156.1 | 12.6 |
| P/B | 4.24 | 1.57 |
| Dividend yield | — | 0.62% |
| Profitability | ||
| Return on equity | 2.7% | 12.4% |
| Net profit margin | 5.0% | 32.8% |
| Operating margin | 14.8% | 30.2% |
| Growth | ||
| Revenue growth (YoY) | -23.1% | -44.7% |
| Net profit growth (YoY) | -149.3% | -57.0% |
| Revenue CAGR (multi-year) | +18.2% | +14.7% |
| Financial health | ||
| Debt to equity | 0.04 | 0.08 |
| Momentum | ||
| 1-month return | -4.8% | -0.4% |
| 1-year return | -44.9% | -2.5% |
| 3-year CAGR | -8.8% | +2.6% |
| 5-year CAGR | -2.9% | -1.5% |
| 10-year CAGR | — | +3.3% |
| Distance from 52W high | -44.3% | -33.1% |
| Technicals | ||
| RSI (14) | 39 | 62 |
| Price vs 200-day avg | +5.9% | -13.0% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Cohance Lifesciences | NATCO Pharma |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✗ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 3/10 | 4/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Cohance Lifesciences or NATCO Pharma?
Cohance Lifesciences has a market cap of ₹16,588 Cr and NATCO Pharma has a market cap of ₹14,445 Cr as of 06 Nov 2026.
Which has a lower P/E, Cohance Lifesciences or NATCO Pharma?
NATCO Pharma has the lower P/E: Cohance Lifesciences trades at 156.1 and NATCO Pharma at 12.6.
Which gave better returns in the last year, Cohance Lifesciences or NATCO Pharma?
NATCO Pharma did better: Cohance Lifesciences returned -44.9% and NATCO Pharma returned -2.5% over one year.
Is Cohance Lifesciences or NATCO Pharma a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Cohance Lifesciences scores 3/10 and NATCO Pharma scores 4/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.